Primary
Immunodeficiency
(Cutaquig-Registry)
Research is at the heart of advancing our knowledge of immune deficiencies.
without people like you, we would not be where we are today.
Do you currently have primary immunodeficiency?
Are you considering switching your treatment to subcutaneous Cutaquig?
Optimed Research, along with Octapharma, is conducting an observational study for patients who have primary immunodeficiency,
and who have not yet switched, but will be switching their treatment to subcutaneous Cutaquig.
The purpose of this study is to gather real-world data regarding the efficacy of Cutaquig in patients who are treated with this product.
Eligibility Criteria
